Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.79 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.45 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467512 | 1.00 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2465454 | 1.00 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2468719 | 1.00 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2463681 | 1.00 | S1PR1 (0.79) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL79956 | 0.90 | S1PR1 (0.63) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2468253 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL12336974 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Amiselimod SCHEMBL2463680 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| Amiselimod SCHEMBL29691985 | 0.89 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL80894 | 0.89 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809304-B2 | Amine compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-1961734-B1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1961734-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | S1PR1 370/4885S1PR3 369/4885S1PR4 451/4885 |
| US-20140296183-A1 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | HRH3, HRH2, HRH4 | S1PR1 370/4885S1PR3 369/4885S1PR4 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.